Literature DB >> 11816163

The HIV vaccine pipeline, from preclinical to phase III.

A M Schultz1, J A Bradac.   

Abstract

Mesh:

Substances:

Year:  2001        PMID: 11816163     DOI: 10.1097/00002030-200100005-00018

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

Authors:  Nia Tatsis; Julie C Fitzgerald; Arturo Reyes-Sandoval; Kimberly C Harris-McCoy; Scott E Hensley; Dongming Zhou; Shih-Wen Lin; Ang Bian; Zhi Quan Xiang; Amaya Iparraguirre; Cesar Lopez-Camacho; E John Wherry; Hildegund C J Ertl
Journal:  Blood       Date:  2007-05-17       Impact factor: 22.113

Review 2.  Advances in FIV vaccine technology.

Authors:  Elizabeth W Uhl; Marcus Martin; James K Coleman; Janet K Yamamoto
Journal:  Vet Immunol Immunopathol       Date:  2008-01-20       Impact factor: 2.046

3.  Stabilizing the native trimer of HIV-1 Env by destabilizing the heterodimeric interface of the gp41 postfusion six-helix bundle.

Authors:  Sannula Kesavardhana; Raghavan Varadarajan
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice.

Authors:  Scott D Parker; Scott T Rottinghaus; Allan J Zajac; Ling Yue; Eric Hunter; Richard J Whitley; Jacqueline N Parker
Journal:  Vaccine       Date:  2007-07-27       Impact factor: 3.641

5.  Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.

Authors:  X Zhan; K S Slobod; S Surman; S A Brown; T D Lockey; C Coleclough; P C Doherty; J L Hurwitz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates.

Authors:  Simon M Agwale; Joseph C Forbi; Frank Notka; Terri Wrin; Jens Wild; Ralf Wagner; Hans Wolf
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.